Peakdale Extends its Range of Medicinal Chemistry Services
News Feb 21, 2006
Peakdale Molecular Ltd has announced the extension of its range of Medicinal Chemistry Services to further support its customers’ drug discovery programmes.
The services enable the Company to provide compounds with a starting point for hit discovery, resulting in significant savings for subsequent optimisation.
The Company has added to its medicinal chemistry expertise and developed computer-aided drug design (CADD) tools that build on its core strength of innovative synthetic chemistry.
Peakdale’s Medicinal Chemistry Services are designed to complement its customers’ drug discovery initiatives through hit-to-lead and lead optimisation projects, patent protection projects, back-up chemotypes and fast follower candidate programmes.
They also include the synthesis of chemogenetic arrays on an exclusive basis utilising Peakdale’s privileged scaffolds. The services are underpinned by Peakdale’s strength in CADD, used to simulate drug-receptor interactions.
The Company’s expertise in this specialist discipline enables its scientists to frontload compounds with beneficial ADMET properties and to construct 3D-QSAR models to identify favourable regions of chemical space.
Commenting on the announcement, Kim Morrison, Peakdale CEO, noted, "The enhancement of our service offering, led by Dr Terry Hart, is a major step in the drive to further support our pharmaceutical and biotech customers’ research and drug discovery programmes and marks a new chapter in the Company’s development."
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE